Conventional vs Reverse Sequence of Neoadjuvant Epirubicin/Cyclophosphamide and Docetaxel
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
British Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Conventional Versus Reverse Sequence of Neoadjuvant Epirubicin/Cyclophosphamide and Docetaxel: Sequencing Results From ABCSG-34
Br. J. Cancer 2021 Mar 24;[EPub Ahead of Print], R Bartsch, CF Singer, G Pfeiler, M Hubalek, H Stoeger, A Pichler, E Petru, V Bjelic-Radisic, R Greil, M Rudas, TM Muy-Kheng, V Wette, AL Petzer, P Sevelda, D Egle, PC Dubsky, M Filipits, F Fitzal, R Exner, R Jakesz, M Balic, C Tinchon, Z Bago-Horvath, S Frantal, M GnantFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.